3rd Quarter - Report
ULTRAGENYX PHARMACEUTICAL INC. for ULTRAGENYX PHARMACEUTICAL INC.
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA KAHLMAN | — |
Budget/Appropriations BUD
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA KAHLMAN | — |
Medicare/Medicaid MMM
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA KAHLMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.